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Capsule Summary:
The EPX histologic scoring system can be used to differentiate children with EoE and PPI-REE 
relative to GERD, supporting the relationship between these 2 groups and enhancing current 
diagnostic and treatment approaches.
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To the Editor:
Distinguishing between eosinophilic esophagitis (EoE), gastroesophageal reflux disease 
(GERD), and proton pump inhibitor-responsive esophageal eosinophilia (PPIREE) is 
difficult because symptoms overlap and there is no pathognomonic histologic feature for 
these disorders(1). Current EoE diagnostic guidelines define EoE as a clinicopathological 
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condition characterized by symptoms of esophageal dysfunction and > 15 eosinophils per 
high power field (eos/HPF) in the esophageal mucosa after ruling out other etiologies as a 
cause of inflammation(1). Treatment with high-dose proton pump inhibitors (PPI) had been 
used in clinical practice to exclude GERD and distinguish it from EoE(1). However, recent 
studies suggest that PPI-REE may represent a subset of patients with EoE(2), suggesting that 
PPIs should be considered as treatment for EoE, rather than simply part of the diagnostic 
algorithm. Enumeration of eosinophils using Hematoxylin & Eosin (H&E) stained biopsy 
sections may underestimate the extent of eosinophil involvement including features such as 
degranulation. We previously developed a histologic scoring system that assessed eosinophil 
peroxidase (EPX) to differentiate adults with EoE from GERD(3). The EPX scoring system 
differentiates intact eosinophils from eosinophil degranulation, as well as quantifying tissue 
distribution patterns of eosinophilia(3). The aim of this study was to assess the ability of the 
EPX scoring system to identify similarities and differences in the pattern of eosinophilic 
inflammation between EoE, PPI-REE and GERD in children. We hypothesized that children 
with EoE and PPI-REE would have similar EPX scores, whereas children with GERD would 
have lower scores.
We conducted a retrospective case control study of pediatric subjects cared forat Children’s 
Hospital Colorado between 2006 and 2016 with EoE, PPI-REE, GERD and normal controls 
(Table). Subjects with EoE were defined according to consensus recommendations(1). 
Subjects with PPI-REE had ≥ 15 eos/HPF and were symptomatically and histologically 
responsive to high dose PPI (1–2 mg/kg/day). Subjects with EoE or PPI-REE, selected for 
this study, demonstrated histologic resolution of esophageal eosinophilia (< 15 eos/HPF) 
after 6–8 weeks of their prescribed treatment. Control subjects had gastrointestinal 
symptoms necessitating upper intestinal endoscopy with normal histology. 
Immunohistochemical staining with an EPX monoclonal antibody and scoring was 
performed as previously described(3). Briefly, this algorithm assesses 5 features: 1) 
maximum eosinophils in a single focus; 2) average number of eosinophils in five 40X high 
power fields; 3) level of degranulation; 4) patchiness or the extent of eosinophil infiltration 
and degranulation in the maximally affected biopsy; and 5) reproducibility or the extent of 
all biopsies with eosinophil infiltration or degranulation. The magnitude of each feature is 
assessed, along with a priority factor for each feature that gives a single numeric value to the 
global characteristics of tissue eosinophilia. (see Supplementary Table in this article’s 
Online Repository at www.jacionline.org). Paired post-treatment esophageal biopsies were 
available for EoE and PPI-REE subjects. This study was approved by the Institutional 
Review Board at Children’s Hospital Colorado (IRB 07–0888). Statistical analysis of data 
was performed by one-way analysis of variance with Tukey’s Post-hoc test and a P-value < 
0.05 was considered statistically significant. GraphPad Prism 7 (GraphPad Software, LaJolla 
CA) was used for statistical analysis.
Paired biopsies, pre- and post-therapy, were analyzed for EoE (n=24) and PPIREE (n=9) 
subjects, while single biopsies were analyzed for GERD (n=28) and control (n=22) subjects. 
EoE patients were treated with swallowed topical corticosteroids (n=10), elimination diet 
(n=7), or a combination of both (n=7). The patient demographics, peak eosinophil count as 
measured by H&E and endoscopic findings for each group are as shown in the Table. 
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Treatment of EoE, with dietary elimination or topical corticosteroids, led to significant 
decreases in each individual parameter of the EPX histologic score (including 
reproducibility, patchiness, degranulation, max eosinophilic infiltrate in single focus, and 
average eosinophilic infiltrate), and in the total EPX score (42.0±1.7 vs 5.1±2.1, P<0.0001) 
(See Figure). Similarly, PPI therapy in PPIREE subjects also led to significant decreases in 
all parameters including total EPX score (40.3±2.5 vs 4.6±2.3, P<0.0001). No statistically 
significant differences were found when comparing EPX scores for EoE and PPI-REE 
before treatment, but EPX scores were significantly elevated in both groups compared to 
GERD (EoE pre-treatment vs GERD, 42.0±1.7 vs. 2.7±1.4, P<0.0001; PPI-REE pre-
treatment vs GERD, 40.3±2.5 vs. 2.7±1.4, P<0.0001). Thus, PPI-REE and EoE scores were 
comparable but both uniquely discernible from GERD.
During the last decade, an accumulating body of evidence supports the view that a 
proportion of patients with clinical features (i.e. symptoms and endoscopic features) and 
histopathologic findings (i.e. mucosal eosinophilia and molecular analytes) consistent with 
EoE respond to PPI(2). In addition to acid-protective effects, PPIs have anti-inflammatory 
properties related to inhibition of eotaxin-3, a chemoattractant involved in the pathogenesis 
of EoE(4). As a result, up to 50% of patients with histologic findings consistent with EoE 
may respond to PPI therapy(5).
Previous studies have evaluated the utility of staining the esophageal epithelium for markers 
associated with EoE, including major basic protein, eotaxin-3, and tryptase in adults, and 
found that these markers are higher in EoE, but do not differentiate between EoE and PPI-
REE(6). Additionally, studies found that tryptase and EPX staining may aid in 
differentiating between EoE and GERD in adults(3, 7). Our study sought to compare 
eosinophilic inflammation in EoE and PPI-REE with a previously described EPX 
immunohistochemical scoring system. Consistent with prior studies, the results demonstrate 
that eosinophilic inflammation in PPI-REE and EoE are similar pre and post-treatment. Our 
results also suggest that EPX staining in these two groups is different from GERD. One 
important strength of this study was inclusion of treatment naïve, PPI-REE subjects; a 
population often excluded in other studies due to the previous diagnostic algorithm, 
however, we acknowledge the limitation of the small sample size of PPI-REE group. 
Recently published updated consensus recommendations suggesting that PPIs may serve as 
treatment for EoE could allow future studies to identify a larger number of subjects who are 
PPI-naïve(2). Another limitation is that subjects with GERD had lower peak eosinophil 
counts than EoE and PPI-REE subjects. Previous studies have shown that esophageal 
eosinophil counts alone do not distinguish EoE and GERD subjects with GERD may have > 
15 eos/HPF; however, this degree of eosinophilic inflammation in GERD is usually 
associated with erosive or microscopic esophagitis. The present study was conducted in 
pediatric subjects where erosive or microscopic esophagitis are less common.
With the emergence of an increasing number of methods to assess the esophagus in patients 
with EoE, enumeration of eosinophils in biopsies as the sole metric for inflammation may be 
limiting. The EPX scoring system assesses eosinophilic infiltration, density, distribution, and 
degranulation. An EoE Histologic Scoring System (EoEHSS) was recently developed by 
Collins et al to evaluate other pathologic features in esophageal biopsies from patients with 
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EoE including basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, 
dilated intercellular spaces, surface epithelial alteration, and dyskeratotic epithelial cells.(8) 
Although the EoEHSS evaluates additional pathologic features beyond peak eosinophil 
count, it does not assess eosinophil degranulation or tissue distribution patterns of 
eosinophilic inflammation in the esophagus, moreover, the EoEHSS has not been correlated 
with symptomatology. In contrast, EPX degranulation is a validated biomarker that 
correlates with pediatric dysphagia – even more strongly than eosinophil counts alone(9). 
While the EPX score did not outperform peak eosinophil counts in terms of diagnostic 
accuracy in this study, it provides a more comprehensive assessment of eosinophil activity. 
In summary, quantification of EPX by our EPX scoring system can be used to differentiate 
children with EoE and PPI-REE relative to GERD and enhance current diagnostic 
approaches.
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eos/HPF Eosinophils per high power field
GERD Gastroesophageal reflux
H&E Hematoxylin & Eosin
PPI Proton pump inhibitor
PPI-REE Proton pump inhibitor-responsive esophageal eosinophilia
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Scores for each EPX histology parameter including A) reproducibility (extent of all biopsies 
with eosinophil infiltration or degranulation), B) patchiness (extent of eosinophil infiltration 
or degranulation in maximally affected biopsy), C) level of degranulation, D) maximum 
eosinophils in a single focus, E) average number of eosinophils in five 40X high power 
fields and F) total EPX Score (EoE n=24, PPI-REE n=9, GERD n=28 and Control n=22, * 
P<0.05, ****P<0.0001).
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